Aethlon Medical to Present at Virtual Investor Conferences in September

Rhea-AI Summary

Aethlon Medical (Nasdaq: AEMD), a company developing products for cancer and infectious diseases, has announced its participation in two virtual investor conferences in September 2024. The events are:

1. Life Sciences Investor Forum (Sept 19-20): James Frakes (Interim CEO/CFO) and Dr. Steven LaRosa (CMO) will present on Sept 19 at 1:30 pm ET. One-on-one meetings available.

2. Virtual Emerging Growth Conference (Sept 25): Presentation at 12:35 pm ET, followed by Q&A.

Both events offer live interaction, pre-registration, and archived webcasts. These conferences provide opportunities for investors to learn about Aethlon Medical's developments and engage with management directly.

News Market Reaction

-1.55%

1 alert

-1.55% News Effect

On the day this news was published, AEMD declined 1.55%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that management will present at the following virtual investor conferences in September:

• September 19-20: Life Sciences Investor Forum: James Frakes, Interim Chief Executive Officer and Chief Financial Officer and Steven LaRosa, MD, Chief Medical Officer, will present a company overview at this conference, hosted by virtualinvestorconferences.com, on Thursday, September 19, 2024 at 1:30 pm ET. Management will also be available for one-on-one meetings on September 19 and 20, 2024.
  
  Interested investors can pre-register for the conference using this link, which will be a live interactive online event where investors can ask the company questions in real-time. An archived webcast will also be available after the event.  

• September 25: Virtual Emerging Growth Conference: Mr. Frakes and Dr. LaRosa will present a company overview at this conference on Wednesday, September 25, 2024 at 12:35 pm ET.
  
  After the presentation, management will open the floor for questions. Investors may submit questions in advance to questions@emerginggrowth.com or ask questions during the event.
  
  Please register using this link to attend the virtual conference and receive any updates that are released.
  
  An archived webcast will also be made available on www.emerginggrowth.com and on the Emerging Growth YouTube Channel, www.YouTube.com/emerginggrowthconference, which will be released after the event.

About Aethlon and the Hemopurifier^®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Additional information can be found at www.AethlonMedical.com.

Company Contact:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com

 

View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-virtual-investor-conferences-in-september-302250041.html

SOURCE Aethlon Medical, Inc.

FAQ

When is Aethlon Medical (AEMD) presenting at the Life Sciences Investor Forum in September 2024?

Aethlon Medical (AEMD) is presenting at the Life Sciences Investor Forum on Thursday, September 19, 2024 at 1:30 pm ET.

Who will be representing Aethlon Medical (AEMD) at the September 2024 investor conferences?

James Frakes, Interim CEO and CFO, and Dr. Steven LaRosa, Chief Medical Officer, will be representing Aethlon Medical (AEMD) at the September 2024 investor conferences.

What is the date and time of Aethlon Medical's (AEMD) presentation at the Virtual Emerging Growth Conference?

Aethlon Medical (AEMD) will present at the Virtual Emerging Growth Conference on Wednesday, September 25, 2024 at 12:35 pm ET.

Are one-on-one meetings available with Aethlon Medical (AEMD) management during the September 2024 conferences?

Yes, one-on-one meetings with Aethlon Medical (AEMD) management are available on September 19 and 20, 2024 during the Life Sciences Investor Forum.

How can investors access the archived webcasts of Aethlon Medical's (AEMD) September 2024 conference presentations?

Archived webcasts will be available after the events on the respective conference websites and, for the Emerging Growth Conference, also on their YouTube channel.